Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 66-year-old patient presented with acute recurrent metastatic estrogen and progesterone receptor-positive, Her-2/neu-negative breast cancer, bone lesions (lumbar spine, pelvis), pulmonary nodules, hepatic metastasis, elevated cancer antigen 15 and liver enzymes, dyspepsia, and diarrhea. The patient had been taking raloxifene for approximately 8 years. After discontinuation, clinical parameters and symptoms improved rapidly without oncological therapy or other forms of treatment. Three months after raloxifene discontinuation, capecitabine was initiated by the treating oncologist who deemed an anti-estrogen withdrawal effect (AEWE) implausible. However, the lasting regression was more indicative of a raloxifene rebound effect than chemotherapy or other interventions. Today, the patient is asymptomatic with a good performance status. Hepatic metastatic regression has been confirmed, without any oncological treatment administered in the past 16 months and approximately 23 months following the withdrawal of raloxifene. This case highlights the need to screen breast cancer patients for the possibility of an AEWE if they are using raloxifene and possibly similar selective estrogen receptor modulators (SERMs) which includes tamoxifen, when diagnosed with advanced breast cancer, especially in the recurrent disease setting.
 ...
PMID:Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report. 2741 56

Dear Editor, We present the case of a 42-year-old woman under study for dyspepsia without response to empirical treatment. She has perioral mucocutaneous pigmentation. Gastroscopy reveals a 5cm gastric tumor in the antrum, as well as multiple sessile gastric and duodenal polyps smaller than 1 cm (fig 1a). Obtaining large-capacity forceps biopsies, a well-differentiated adenocarcinoma with gastric origin is diagnosed, with over expression of the HER2/neu without microsatellite instability in the context of a hamartomatous polyposis. The genomic study confirms an alteration in the STK11 gene translated to a truncated protein product, compatible with a Peutz-Jeghers syndrome (PJS). In the endoscopic ultrasound study the lesion appears as a heteroecogenic mass with anechoic areas and microcalcifications, arising from the superficial layers of the gastric wall, respecting the muscular layer. The lesion contacts without infiltrating the pancreatic parenchyma which is normal (fig 1b). The study is completed by small-bowel capsule endoscopy (CE) in which multiple micropolyps are observed all along the duodenum, jejunum and ileum; detecting several of them larger than 10mm in the proximal jejunum and the ileum. CT scan shows lymph node and peritoneal involvement. Given the extension, systemic therapy is started with partial response. It is decided to perform cytoreductive surgery (total gastrectomy, right hemicolectomy due to wall implants and resection of distal ileum due to larger than 10mm polyps) and large polyps mucosectomy in the proximal jejunum by anterograde enteroscopy, after which a second-line chemotherapy is started. Discussion PJS is a hamartomatous polyposis that is characterized by a high cumulative risk of cancer in different locations; although gastric malignancy (adenocarcinoma), as in the case we present, is not the most common (1-2). In this type of polyposis, it is important to study the small bowel using CE to define number, location and size of the polyps, as well as identifying the enteroscopy access route which is indicated in symptomatic patients, polyps larger than 10mm or rapid growth (2-4).
 ...
PMID:PRIMARY GASTRIC ADENOCARCINOMA IN PATIENT WITH PEUTZ-JEGHERS SYNDROME. 3324 76